These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9199040)

  • 1. [Immunotherapy of metastatic renal cell carcinoma. Is clinical use justified in view of outcome, side effects and costs?].
    Oberneder R; Kriegmair M; Staehler M; Hofstetter A
    Urologe A; 1997 Mar; 36(2):130-7. PubMed ID: 9199040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic factors for predicting the success of immunotherapy in metastatic renal cell carcinoma].
    Schmitz-Dräger BJ; Jankevicius F; Otto T
    Urologe A; 1995 May; 34(3):195-9. PubMed ID: 7610511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal cell carcinoma: novel treatments for advanced disease.
    Huland E; Heinzer H
    Curr Opin Urol; 2003 Nov; 13(6):451-6. PubMed ID: 14560137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for renal cell carcinoma.
    Bleumer I; Oosterwijk E; De Mulder P; Mulders PF
    Eur Urol; 2003 Jul; 44(1):65-75. PubMed ID: 12814677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunotherapy of renal cell carcinoma. With special emphasis on therapy of the elderly patient].
    Heinzer H; Huland E; Huland H
    Urologe A; 2003 Nov; 42(11):1450-2. PubMed ID: 14624342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cytokine therapy of metastatic renal cell carcinoma].
    Otto T; Goepel M; Luboldt HJ; Rübben H
    Urologe A; 1995 May; 34(3):200-3. PubMed ID: 7610512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Are immunotherapy and chemotherapy in metastatic renal cell cancer out?].
    Schmitz-Dräger BJ
    Urologe A; 1992 Jul; 31(4):213-4. PubMed ID: 1514204
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for renal cell carcinoma.
    Rosenblatt J; McDermott DF
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):793-812. PubMed ID: 21763968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving role of cytoreductive surgery for metastatic renal cell carcinoma.
    Chaudhary UB; Hull GW
    Oncology (Williston Park); 2003 May; 17(5):701-5; discussion 705-6, 711-2. PubMed ID: 12800795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
    Atzpodien J; Kirchner H; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunotherapy of metastatic renal cell cancer].
    Manseck A; Wirth M
    Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature.
    Rebuzzi SE; Bregni G; Grassi M; Damiani A; Buscaglia M; Buti S; Fornarini G
    Immunotherapy; 2018 Sep; 10(13):1123-1132. PubMed ID: 30236027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urologic approaches to metastatic renal cell carcinoma.
    Mickisch GH
    Onkologie; 2001 Apr; 24(2):122-6. PubMed ID: 11441290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
    Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
    J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of immunotherapy for metastatic renal cell carcinoma.
    Fowler JE
    J Urol; 1986 Jan; 135(1):22-5. PubMed ID: 3510318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology].
    van Herpen CM; de Mulder PH
    Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2613-8. PubMed ID: 10028361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.